Plural Nitrogens In The N-hetero Ring (e.g., Triazoles, Etc.) Patents (Class 536/28.7)
  • Publication number: 20150143553
    Abstract: In an aspect, the invention relates to a method of screening for a therapeutic for amyotrophic lateral sclerosis. In an aspect, the invention relates to transgenic Drosophila. In an aspect, the invention relates to a Drosophila model of amyotrophic lateral sclerosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: October 7, 2014
    Publication date: May 21, 2015
    Inventors: Daniela Zarnescu, Patricia S. Estes
  • Publication number: 20150005245
    Abstract: Sialic acid derivatives of the formula (I) in which the symbols have the definitions stated in the description are suitable as medicaments, more particularly for diseases whose course is influenced by Siglec ligands.
    Type: Application
    Filed: December 21, 2012
    Publication date: January 1, 2015
    Inventors: Reinhard Brossmer, Horst Prescher
  • Publication number: 20140288295
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer.
    Type: Application
    Filed: June 6, 2014
    Publication date: September 25, 2014
    Inventors: Bo-Liang Deng, Timothy A. Riley, Jennifer Riggs-Sauthier
  • Publication number: 20140274936
    Abstract: A coordination complex having a physiologically acceptable pKa includes a metal and a biologically active agent. The pKa of the coordination complex is less than the pKa of the biologically active agent. A pharmaceutical solution for treating a patient includes a coordination complex and water, wherein the coordination complex is at least partially soluble in the water at physiological pH and in a therapeutically efficacious concentration. A method for treating a patient includes administering a pharmaceutical solution including a coordination complex and water to a patient in need of a biologically active agent.
    Type: Application
    Filed: May 29, 2014
    Publication date: September 18, 2014
    Applicant: SYNTHONICS, INC.
    Inventors: Thomas Piccariello, John D. Price, Robert A. Oberlender, Michaela E. Mulhare, Mary C. Spencer, Scott B. Palmer
  • Publication number: 20140243283
    Abstract: The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.
    Type: Application
    Filed: December 18, 2013
    Publication date: August 28, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Yeeman K. Ramtohul, Sanjoy Kumar Das, Caroline Cadilhac, Thumkunta Jagadeeswar Reddy, Louis Vaillancourt, Michel Gallant, Bingcan Liu, Evelyne Dietrich, Frederic Vallee, Julien Martel, Carl Poisson
  • Publication number: 20140234216
    Abstract: The present invention is directed towards new trifunctional folate-conjugates comprising a folate, an albumin binder and a radionuclide-based therapeutic or diagnostic moiety as well as pharmaceutical compositions thereof, their method of production and their use in diagnostic and therapeutic medical applications, such as diagnostic nuclear imaging and radionuclide therapy.
    Type: Application
    Filed: August 10, 2012
    Publication date: August 21, 2014
    Applicant: MERCK & CIE
    Inventors: Roger Schibli, Rudolf Moser, Cristina Magdalena Muller, Harriet Struthers, Viola Groehn, Simon Mensah Ametamey, Cindy Ramona Fischer
  • Publication number: 20140193337
    Abstract: The present invention is directed towards new 18F-folate radiopharmaceuticals, wherein the 18F isotope is linked via a prosthetic group, more specifically via a prosthetic group having a saccharide group, such as a cyclic mono- or oligosaccharide, preferably based on a pyranoside or furanoside, which is covalently linked to the glutamate portion of a folate or derivative thereof, a method of their preparation, as well as their use in diagnosis and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.
    Type: Application
    Filed: August 21, 2012
    Publication date: July 10, 2014
    Applicant: MERCK & CIE
    Inventors: Roger Schibli, Rudolf Moser, Cristina Magdalena Muller, Simon Mensah Ametamey, Cindy Ramona Fischer, Viola Groehn
  • Publication number: 20140179626
    Abstract: Acadesine derivatives as a drug, as well as the derivatives for the treatment of cancer and in particular for the treatment of chronic myeloid leukemia are described. Also, product containing the derivatives and at least one second active ingredient as a combination product for simultaneous, separate or sequential administration, in the treatment of cancer, as well as a pharmaceutical composition containing the derivatives and a pharmaceutically acceptable carrier are described. Finally, a method for inhibiting the in vitro cell proliferation including the placement of an in vitro cell in contact with the derivatives and methods for synthesis of said derivatives and methods for synthesis of the derivatives are described.
    Type: Application
    Filed: April 17, 2012
    Publication date: June 26, 2014
    Inventors: Rachid Benhida, Patrick Auberger, Vincent Malnuit, Mohsine Driowya, Alexandre Puissant, Guillaume Robert
  • Publication number: 20140120069
    Abstract: The present invention describes novel amphoteric materials based on crosslinked hyaluronic acid, according to the general formula (I), and a method of preparation of said materials. Further, the invention relates to the material containing entrapped active agents (e.g. drugs, growth factors etc.) and a method of preparation thereof. Moreover, the present invention relates to the use of said materials for controlled release systems, in tissue engineering, wound dressing or tissue regeneration.
    Type: Application
    Filed: April 19, 2012
    Publication date: May 1, 2014
    Applicant: CONTIPRO BIOTECH S.R.O.
    Inventors: Gloria Huerta-Angeles, Drahomira Chladkova, Radovan Buffa, Sofiane Kettou, Vladimir Velebny
  • Patent number: 8629266
    Abstract: Starch-based dextrin adhesive additives and methods of preparation are described. Adhesives containing the additive exhibit antimicrobial properties and increased water solubility. The additive contains at least one sugar unit, at least one polyphenol side chain, and at least one Frechet-type poly(aryl ether)dendron.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: January 14, 2014
    Assignee: Empire Technology Development LLC
    Inventor: Glen Leon Brizius
  • Patent number: 8563526
    Abstract: The present invention relates to novel compounds of formula (A): in the form of a free base or of an addition salt with an acid. The invention also relates to process of preparation of compounds of formula (A), to composition comprising them and to their application in therapeutics and in particular in cancers.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: October 22, 2013
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (C.N.R.S.)
    Inventors: Ling Peng, Palma Rocchi, Juan Iovanna, Yi Xia, Fanqi Qu, Jinqiao Wan, Yang Liu, Menghua Wang
  • Publication number: 20130172284
    Abstract: The invention relates to the novel use of 1-beta-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide for the treatment of infectious salmon anaemia caused by the infectious salmon anaemia or ISA virus in salmonids.
    Type: Application
    Filed: June 8, 2010
    Publication date: July 4, 2013
    Applicant: LABORATORIO DE DIAGNOSTICO GAM, S.A.
    Inventors: Ana Maria Sandino, Geraldine Mlynarz Zylberberg, Matilde Jashes Morgues, Eugenio Spencer Ossa
  • Patent number: 8466276
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: June 18, 2013
    Assignee: Nektar Therapeutics
    Inventors: Bo-Liang Deng, Timothy A. Riley, Jennifer Riggs-Sauthier
  • Publication number: 20130116422
    Abstract: Starch-based dextrin adhesive additives and methods of preparation are described. Adhesives containing the additive exhibit antimicrobial properties and increased water solubility. The additive contains at least one sugar unit, at least one polyphenol side chain, and at least one Frechet-type poly(aryl ether)dendron.
    Type: Application
    Filed: October 12, 2012
    Publication date: May 9, 2013
    Applicant: EMPIRE TECHNOLOGY DEVELOPMENT LLC
    Inventor: EMPIRE TECHNOLOGY DEVELOPMENT LLC
  • Publication number: 20130116206
    Abstract: There is provided compounds of formula (I), wherein R1, R2, X1, X2, and X3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as positron emission tomography (PET) imaging agents, useful in the treatment of diseases in which inhibition of epidermal growth factor receptor tyrosine kinase activity or the inhibition of HER2 activity is desired and/or required, and useful in the treatment of cancer.
    Type: Application
    Filed: December 22, 2010
    Publication date: May 9, 2013
    Applicant: IMPERIAL INNOVATIONS LIMITED
    Inventors: Federica Pisaneschi, Alan Spivey, Graham Smith, Eric Aboagye
  • Publication number: 20120309701
    Abstract: The present invention encompasses compounds and methods for treating urinary tract infections.
    Type: Application
    Filed: April 23, 2012
    Publication date: December 6, 2012
    Applicant: THE WASHINGTON UNIVERSITY
    Inventors: James W. Janetka, Zhenfu Han, Scott Hultgren, Jerome S. Pinkner, Corinne Cusumano
  • Publication number: 20120201883
    Abstract: A composition which includes a carboxamide, preferably ribavirin, for treating viral diseases in humans. A preferred embodiment of the subject invention comprises a very high dose (>600 mg) of ribavirin, and more preferably between about 800-1200 mg of ribavirin or more per dosage form.
    Type: Application
    Filed: December 9, 2010
    Publication date: August 9, 2012
    Applicant: ACCU-BREAK Technologies, Inc
    Inventors: Elliot Hahn, Robert I. Goldfarb, Lawrence Solomon, Allan S. Kaplan
  • Publication number: 20120202763
    Abstract: Compounds that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of reducing VEGF using such Compounds and methods for treating cancer and non-neoplastic conditions involving the administration of such Compounds. Further described are methods of inhibiting viral replication or the production of viral RNA or DNA or viral protein using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.
    Type: Application
    Filed: May 27, 2010
    Publication date: August 9, 2012
    Applicant: PTC THERAPEUTICS, INC
    Inventors: Neil Almstead, Tamil Arasu, Soongyu Choi, Liangxian Cao, Jeffrey Allen Campbelll, Donald Corson, Thomas W. Davis, Jason D. Graci, Zhengxian Gu, Peter Seong Woo Hwang, William Lennox, Harry H. Miao, Langdon Miller, Young-Choon Moon, Hongyan Qi, Christopher Trotta, Marla L. Weetall
  • Patent number: 8183216
    Abstract: A class of nucleoside derivatives of formula (I), as defined herein, that are useful as inhibitors of RNA-dependent RNA viral replication and in particular HCV replication, are provided. Also provided are processes for the synthesis and use of such compounds for treating or preventing HCV infection. formula (I).
    Type: Grant
    Filed: September 16, 2008
    Date of Patent: May 22, 2012
    Assignee: Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Maria Emilia Di Francesco, Vincenzo Summa, Gabriella Dessole
  • Publication number: 20120070415
    Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. Examples of viral infections include a respiratory syncytial viral (RSV) and influenza infection.
    Type: Application
    Filed: September 19, 2011
    Publication date: March 22, 2012
    Applicant: ALIOS BIOPHARMA, INC.
    Inventors: Leonid Beigelman, Jerome Deval, David Bernard Smith, Guangyi Wang, Vivek Kumar Rajwanshi
  • Patent number: 7981930
    Abstract: Kits comprising an M2 inhibitor selected from amantadine and rimantadine; ribavirin, and a neuraminidase inhibitor (NAi) in an amount that is antivirally effective in the combination, an oral dosage form containing 75-250 mg of the M2 inhibitor, an oral dosage form comprising 100-400 mg of ribavirin and a neuraminidase inhibitor are provided for the treatment of influenza. Some embodiments of the kits comprise an oral dosage form containing 75-250 mg of the M2 inhibitor, an oral dosage form comprising 100-400 mg of ribavirin, and a neuraminidase inhibitor.
    Type: Grant
    Filed: February 29, 2008
    Date of Patent: July 19, 2011
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Jack Nguyen, Gregory T. Went, Paul Spence, Timothy J. Fultz, David Chernoff, Terry L. Burkoth, Rowan Chapman, Mickey S. Urdea
  • Publication number: 20110136754
    Abstract: The present invention relates to novel compounds of formula (A): in the form of a free base or of an addition salt with an acid. The invention also relates to process of preparation of compounds of formula (A), to composition comprising them and to their application in therapeutics and in particular in cancers.
    Type: Application
    Filed: April 29, 2009
    Publication date: June 9, 2011
    Inventors: Ling Peng, Palma Rocchi, Juan Iovanna, Yi Xia, Fanqi Qu, Jinqiao Wan, Yang Liu, Menghua Wang
  • Publication number: 20110117054
    Abstract: To provide a pharmaceutical agent that is effective for the amelioration or the like of a condition where the prothrombin time is prolonged or a condition where the INR (international normalized ratio) is increased. Disclosed is a pharmaceutical agent comprising ribavirin or a derivative thereof as an active ingredient.
    Type: Application
    Filed: August 27, 2008
    Publication date: May 19, 2011
    Applicant: National University Corporation Nagoya University
    Inventors: Takashi Honda, Junki Takamatsu, Hidenori Toyoda, Koji Yamamoto, Hidemi Goto
  • Publication number: 20110045535
    Abstract: It is intended to provide an activator for blood coagulation factor VII. Ribavirin or its derivative is used as an activator for blood coagulation factor VII promoter.
    Type: Application
    Filed: August 27, 2008
    Publication date: February 24, 2011
    Applicant: National University Corporation Nagoya University
    Inventors: Takashi Honda, Junki Takamatsu, Hidenori Toyoda, Koji Yamamoto, Hidemi Goto, Tetsuhito Kojima
  • Publication number: 20110039797
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer.
    Type: Application
    Filed: February 20, 2009
    Publication date: February 17, 2011
    Applicant: Nektar Therapetics
    Inventors: Bo-Liang Deng, Timothy A. Riley, Jennifer Riggs-Sauthier
  • Patent number: 7858660
    Abstract: Compositions, kits and methods are provided for the treatment or prophylaxis of influenza.
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: December 28, 2010
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Jack Nguyen, Gregory T. Went, Paul Spence, Timothy J. Fultz, David Chernoff, Terry L. Burkoth, Rowan Chapman, Mickey S. Urdea
  • Publication number: 20100166780
    Abstract: The invention relates to oligonucleotides including at least one lipophilic substituted nucleotide analog and a pyrimidine-purine dinucleotide. The invention also relates to pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: September 27, 2007
    Publication date: July 1, 2010
    Inventors: Harald Debelak, Eugen Uhlmann, Marion Jurk
  • Publication number: 20100143980
    Abstract: The present invention includes a xyloside for use in inducing synthesis of a glycosaminoglycan in a cell, the xyloside having a chemical structure of one of Formula (1), Formula (2), Formula (3), Formula (4), Formula (5), Formula (6), Formula (7), Formula (8), Formula (9), or Formula (10) as shown herein. Also, the present invention includes a method of making a xyloside for use in inducing synthesis of a glycosaminoglycan in a cell, wherein the method is performed with “Click” chemistry. Additionally, the present invention includes a method of administering a xyloside so as to induce synthesis of a glycosaminoglycan in a cell.
    Type: Application
    Filed: February 15, 2008
    Publication date: June 10, 2010
    Inventors: Kuberan Balagurunathan, Ethirajan Manivannan, V. Victor Xylophone, Vy My Tran, Khiem Nguyen
  • Publication number: 20100129317
    Abstract: Azole nucleosides represented by the formulae (I) and (II); wherein A=C or N B?C or N X?H; C1-C6 alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclo, halogen such as F, Cl, Br and I; OH, NH2, NH—(C1-C6 alkyl, cycloalkyl, aryl or heterocyclo); Z?H; C1-C6 alkyl, cycloalkyl, alkynyl, aryl, heterocyclo, halogen such as F, Cl, Br, I; OH NH2, NH—(C1-C6 alkyl, cycloalkyl, aryl or heterocyclo; E=(CH2)HONHR; n is an interger from 0-6 and more typically 0-3; R1= aryl or heterocyclo; each of W, Y, R is individually selected from the group consisting of H; C1-C6 alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclo, halogen such as F, Cl, Br, and I; O, OH, Oalkyl, Oaryl, NH2, NH(C1-C6 alkyl, cycloalkyl, aryl or heterocyclo); provided that at least one of W, Y, and R is other than H and wherein both W and Y together can be ?O; and each D individually is OH, Oalkyl, Oaryl, FL and H; pharmaceutically acceptable salts thereof, prodrugs thereof and mixtures thereof are provided.
    Type: Application
    Filed: September 11, 2007
    Publication date: May 27, 2010
    Applicant: SOUTHERN RESEARCH INSTITUTE
    Inventors: Jeffrey B. Arterburn, Colleen B. Jonsson, William B. Parker
  • Publication number: 20100029579
    Abstract: The invention provides a new class of compounds exhibiting an inhibitory effect on neuraminidase (NA), hemagglutinin (HA) and structural M2 protein bearing viruses. These compounds are also useful as inhibitors of the replication factors of hepatitis virus type C (HVC). The invention also describes pharmaceutical compositions containing the compounds of the invention either alone or in combination admixed with a suitable and pharmaceutically acceptable carrier.
    Type: Application
    Filed: January 22, 2008
    Publication date: February 4, 2010
    Applicant: Therapicon Srl
    Inventors: Paolo Alberto Veronesi, Pablo Eduardo Andres Rodriguez, Emanuela Peschechera, Susanna Lucia Veronesi
  • Publication number: 20090240030
    Abstract: This invention provides methods for covalently affixing a biomolecule to either a second molecule or a solid surface using 1,3-dipolar cycloaddition chemistry. This invention also provides related methods and compositions.
    Type: Application
    Filed: December 19, 2008
    Publication date: September 24, 2009
    Inventors: Jingyue Ju, Tae Seok Seo
  • Patent number: 7534771
    Abstract: Disclosed are compounds, compositions and methods for treating viral infections caused by a Flaviviridae family virus, such as hepatitis C virus.
    Type: Grant
    Filed: February 28, 2006
    Date of Patent: May 19, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Jesse Daniel Keicher, Christopher Don Roberts
  • Patent number: 7524825
    Abstract: Disclosed are compounds represented by formulae I, II, and III, and the compositions and methods thereof for treating viral infections caused by a Flaviviridae family virus.
    Type: Grant
    Filed: February 28, 2006
    Date of Patent: April 28, 2009
    Assignee: SmithKline Beecham Corporation
    Inventor: Jesse Daniel Keicher
  • Publication number: 20090042820
    Abstract: Novel tubulin binding compounds and hypoxia activated prodrugs of novel and known tubulin binding compounds useful for treating cancer and other hyperproliferative diseases are disclosed.
    Type: Application
    Filed: November 17, 2005
    Publication date: February 12, 2009
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Xiaohong Cai
  • Patent number: 7285659
    Abstract: A process for the preparation of ribavirin on an industrial scale is described which comprises the reaction of glycosylation of 3-substituted triazoles in the presence of a Lewis acid. Said process comprises: a) the reaction of a triazole of the formula ?with a protected ribofuranose of the formula b) the removal of the Pg groups and, optionally, the conversion into a carboxyamide group of the R2 group of the compound obtained of the formula ?DD/mac—01.07.02.
    Type: Grant
    Filed: July 29, 2002
    Date of Patent: October 23, 2007
    Assignee: Archimica S.r.l.
    Inventors: Aldo Banfi, Bruno Dall'Oro, Marco Frigerio, Alfredo Mancini
  • Patent number: 7285660
    Abstract: A process for the preparation of L-ribavirin on an industrial scale is described which comprises the reaction of glycosylation of 3-substituted triazoles in the presence of a Lewis acid.
    Type: Grant
    Filed: July 25, 2002
    Date of Patent: October 23, 2007
    Assignee: Archimica S.r.l.
    Inventors: Aldo Banfi, Bruno Dall'Oro, Marco Frigerio, Alfredo Mancini
  • Patent number: 7268119
    Abstract: Nucleosides and nucleotides containing a tricyclic base portion thereof are useful for treating infectious diseases and proliferative disorders, such as viral infections or cancer respectively.
    Type: Grant
    Filed: February 14, 2007
    Date of Patent: September 11, 2007
    Assignee: Biota Scientific Management Pty Ltd
    Inventors: Phillip Dan Cook, Deborah K. Ewing, legal representative, Yi Jin, John Lambert, Marija Prhavc, Vasanthankumar Rajappan, Vivek K. Rajwanshi, Kandasamy Sakthivel, Gregory Ewing, deceased
  • Patent number: 7083961
    Abstract: The invention provides a crystalline complex containing T. foetus IMPDH in complex with inosine monophosphate (IMP), the complex specified by disclosed atomic coordinates. Also provided are crystalline complexes of containing T. foetus IMPDH with both inosine monophosphate (IMP) and mycophenolic acid, with both xanthosine monophosphate (XMP) and mycophenolic acid, with both xanthosine monophosphate (XMP) and nicotinic adenine dinucleotide (NAD), with ribovirin (1-?-D-ribofuranosyl-1,2,4-triazole-3-carboxamide, and with both ribovirin and mycophenolic acid, each complex specified by disclosed atomic coordinates. Also provided by the invention are the atomic coordinates for these complexes. Further provided by the invention are methods for identifying modulations of IMPDH that employ the atomic coordinates of the invention.
    Type: Grant
    Filed: September 15, 2003
    Date of Patent: August 1, 2006
    Assignee: Regents of the University of California
    Inventors: Hartmut Luecke, Glen Prosise
  • Patent number: 7022830
    Abstract: Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.
    Type: Grant
    Filed: November 26, 2002
    Date of Patent: April 4, 2006
    Assignee: Tripep AB
    Inventor: Matti Sallberg
  • Patent number: 6960569
    Abstract: Disclosed herein is the discovery of a novel hepatitis C virus (HCV) isolated from a human patient. Embodiments of the inevntion include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as, methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.
    Type: Grant
    Filed: August 15, 2001
    Date of Patent: November 1, 2005
    Assignee: TRIPEP AB
    Inventor: Matti Sällberg
  • Patent number: 6930093
    Abstract: A method for the prophylaxis or treatment of an inflammatory bowel disease is provided, comprising administering to a patient having or at risk of developing an inflammatory bowel disease a therapeutically or preventatively effective amount of one or more ribofuranose derivatives having the Formula (I): wherein R is a group selected from a carboxamide, an amidine, and pharmaceutically acceptable acid addition salts thereof, and the configuration at the C2 carbon of the ribofuranose moiety is D or L. The one or more ribofuranose derivatives (I) may be used in combination with further active agents such as antivirals or agents effective against inflammatory bowel disease.
    Type: Grant
    Filed: July 10, 2003
    Date of Patent: August 16, 2005
    Assignee: Valeant Research & Development
    Inventor: Victor Brantl
  • Patent number: 6924270
    Abstract: Ribavirin derivatives represented by the formula II, pharmaceutical compositions containing them as well as methods of using the ribavirin derivatives represented by the formula II for the treatment of susceptible viral infections, for example, chronic hepatitis C infections administrating, the ribavirin derivatives being represented by formula II are disclosed.
    Type: Grant
    Filed: April 18, 2001
    Date of Patent: August 2, 2005
    Assignee: Schering Corporation
    Inventors: Ashit K. Ganguly, Jinping Mc Cormick, Raymond G. Lovey, Frank Bennett, Anil K. Saksena, Viyyoor M. Girijavallabhan
  • Patent number: 6900298
    Abstract: A process for efficiently producing a nucleic acid derivative by condensing a specific nitrogen-containing heterocyclic compound such as a dinitrogen 6-membered heterocyclic compound or a trinitrogen 5-membered heterocyclic compound with a pentose using a less expensive and safe reagent. Namely, a process for producing a nucleic acid derivative by condensing a dinitrogen 6-membered heterocyclic compound or a trinitrogen 5-membered heterocyclic compound with a pentose in the presence of an iron halide.
    Type: Grant
    Filed: February 11, 2003
    Date of Patent: May 31, 2005
    Assignee: Mitsubishi Chemical Corporation
    Inventors: Yuki Takuma, Kyoko Endo, Takeshi Murakami, Tomoko Maeda, Tomoko Sasaki, Youichi Matsumoto
  • Patent number: 6858590
    Abstract: Compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans are disclosed. More particularly, vaccine compositions comprising ribavirin and an antigen, preferably an antigen that has an epitope present in Hepatitis C virus (HCV), are disclosed for use in treating and preventing disease, preferably HCV infection.
    Type: Grant
    Filed: August 15, 2001
    Date of Patent: February 22, 2005
    Assignee: TRIPEP AB
    Inventors: Matti Sällberg, Catharina Hultgren
  • Patent number: 6846918
    Abstract: This invention discloses a method for the preparation of 2?-modified nucleosides, using a palladium catalyst and an alkene functionalized with a heteroatom. Included in the invention are the novel pyrimidines and purines that can be prepared according to the method of the invention and oligonucleotides containing said modified pyrimidines and purines.
    Type: Grant
    Filed: January 24, 2003
    Date of Patent: January 25, 2005
    Assignee: Gilead Sciences, Inc.
    Inventors: Jeffrey T. Beckvermit, Chi Tu
  • Publication number: 20040259819
    Abstract: Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof.
    Type: Application
    Filed: December 12, 2003
    Publication date: December 23, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Wendelin Frick, Heiner Glombik, Werner Kramer, Hubert Heuer, Harm Brummerhop, Oliver Plettenburg
  • Patent number: 6815542
    Abstract: Nucleosides, novel nucleoside analog compounds and their novel prodrug forms are disclosed. The novel compounds, prodrugs, or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Type 1 and Type 2 activity.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: November 9, 2004
    Assignee: Ribapharm, Inc.
    Inventors: Zhi Hong, Jean-Luc Girardet, Kanda Ramasamy, Johnson Lau
  • Publication number: 20040192904
    Abstract: A process for the preparation of ribavirin on an industrial scale is described which comprises the reaction of glycosylation of 3-substituted triazoles in the presence of a Lewis acid.
    Type: Application
    Filed: January 30, 2004
    Publication date: September 30, 2004
    Inventors: Aldo Banfi, Bruno Dall'Oro, Marco Frigerio, Alfredo Mancini
  • Patent number: 6790837
    Abstract: A liquid formulation comprising ribavirin having a longer shelf life and improved taste is disclosed.
    Type: Grant
    Filed: October 31, 2002
    Date of Patent: September 14, 2004
    Assignee: Schering Corporation
    Inventors: Susan K. Heimbecher, Joel A. Sequeira
  • Publication number: 20040176587
    Abstract: A process for the preparation of L-ribavirin on an industrial scale is described which comprises the reaction of glycosylation of 3-substituted triazoles in the presence of a Lewis acid and of a solvent. Said process comprises: a) the reaction of a triazole of formula (I) with a protected L-ribofuranose of formula (II)b) the removal of the Pg groups and, optionally, the conversion into a carboxyamide group of the R2 group of the compound obtained of formula (III) to give L-ribavirin.
    Type: Application
    Filed: January 30, 2004
    Publication date: September 9, 2004
    Inventors: Aldo Banfi, Bruno Dall'Oro, Marco Frigerio, Alfredo Mancini